Mantacore

Mantacore Therapeutics is a South San Francisco-based biotechnology company dedicated to discovering and developing small molecule therapeutics for neurological and neuropsychiatric disorders. The company was co-founded by Dr. David Bredt, a renowned neuroscientist and former executive at Janssen and Eli Lilly, in collaboration with MPM Capital. Mantacore's research platform centers on the modulation of synaptic transmission and protein-protein interactions involved in brain signaling. While currently operating in a relatively quiet phase, the company is building a pipeline of precision medicines aimed at treating complex CNS conditions with high unmet medical needs. Its approach combines advanced chemical biology with deep insights into the molecular architecture of the synapse to create highly specific therapeutic candidates.